Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
09:54am, Thursday, 04'th Aug 2022 Benzinga
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
ECMOHO Limited (NASDAQ: MOHO) jumped 146.1% to settle at $0.4085 on a
Moderna, PayPal And Some Other Big Gainers From Wednesday
08:00am, Thursday, 04'th Aug 2022 Benzinga
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.
Ping Identity Holding Corp. (NYSE:
Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
04:59pm, Wednesday, 03'rd Aug 2022 Benzinga
Gainers
Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Kaspien Holdings Inc. (NASDAQ: KSPN) gained 112.4% to $5.48.
Eargo, Inc. (NASDAQ: E
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
04:14pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?
03:58pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
2 Growth Stocks That Are Unapologetically Crushing the Bear Market
02:15pm, Tuesday, 02'nd Aug 2022 The Motley Fool
There's more than one factor driving recent outperformance of these shares.
Will Fusion Pharmaceuticals Inc. (FUSN) Report Negative Q2 Earnings? What You Should Know
02:00pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
04:31pm, Monday, 01'st Aug 2022 Zacks Investment Research
Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
04:29pm, Monday, 01'st Aug 2022 Zacks Investment Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
03:40pm, Monday, 01'st Aug 2022 Zacks Investment Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
03:13pm, Monday, 01'st Aug 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
07:51pm, Friday, 29'th Jul 2022 Zacks Investment Research
On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
02:51pm, Friday, 29'th Jul 2022 Zacks Investment Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
What is in Store for Regeneron (REGN) This Earnings Season?
02:20pm, Friday, 29'th Jul 2022 Zacks Investment Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
04:20pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
